Bioinformatics company Prenosis has secured USD 4.8 million in Phase II SBIR grants from the National Institute of General Medical Sciences (NIGMS). This brings the total funds raised by the company to USD 11.5 million.
The funding is expected to support the development and utilization of Prenosis’ Immunix platform for predictive diagnostics, clinical decision support tools, improved clinical trials, and precision medicine drugs for sepsis.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.